These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19304957)

  • 1. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
    Ho PA; Alonzo TA; Gerbing RB; Pollard J; Stirewalt DL; Hurwitz C; Heerema NA; Hirsch B; Raimondi SC; Lange B; Franklin JL; Radich JP; Meshinchi S
    Blood; 2009 Jun; 113(26):6558-66. PubMed ID: 19304957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
    Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
    Ho PA; Zeng R; Alonzo TA; Gerbing RB; Miller KL; Pollard JA; Stirewalt DL; Heerema NA; Raimondi SC; Hirsch B; Franklin JL; Lange B; Meshinchi S
    Blood; 2010 Aug; 116(5):702-10. PubMed ID: 20413658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
    J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
    Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
    Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
    Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
    Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
    Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
    Mizushima Y; Taki T; Shimada A; Yui Y; Hiraumi Y; Matsubara H; Watanabe M; Watanabe K; Kamitsuji Y; Hayashi Y; Tsukimoto I; Kobayashi R; Horibe K; Tawa A; Nakahata T; Adachi S
    Int J Hematol; 2010 Jun; 91(5):831-7. PubMed ID: 20495894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.